Development and Characterization of Colloidally Stable Dendrimer–Botox Conjugates for Targeted Muscle Delivery and Radiolabeled Imaging
Pharmaceutical Sciences · 30.04.2026 · 32 (2) · 201-218
DOI: 10.34172/ps.026.42832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 30.04.2026. Verfasst von Nazanin Ajdary und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Background
Botox’s therapeutic applications are limited by its instability and uncontrolled diffusion into extramuscular tissues. This study aims to develop a polyethylene glycol-based formulation by conjugating Botox to a second-generation anionic linear-globular dendrimer (G2-ALGDs) and evaluate its colloidal stability and muscle localization using technetium-99m radioimaging.
Methods
G2-ALGDs were synthesized via N,N′-dicyclohexylcarbodiimide catalysis and conjugated with Botox (D-BTX) using EDC/DCC coupling. Characterization was done by DLS, FTIR, AFM, TEM, and FE-SEM. Stability at 4 °C was monitored for six months using DLS and TEM. Cytocompatibility was assessed by MTT assay in HFF2 cells. D-BTX was radiolabeled with technetium-99m to study purity, stability, and in vivo biodistribution using RT-LC and SPECT imaging.
Results
Botox conjugation increased the particle size from 111.6±16.9 nm to 160.0±3.1 nm and shifted the zeta potential from –25.2±1.63 mV to+17.16±1.24 mV. FTIR confirmed amide bond formation at 1649 cm⁻¹. D-BTX was much less cytotoxic than free Botox at 0.001 ng/mL (p=0.0013), but no difference was observed at higher concentrations. The formulation exhibited physical stability for six months at 4°C. The radiolabeled formulation was up to 90.85% pure and remained stable for 24 h. SPECT imaging revealed improved localization of D-BTX within the muscle. After 12 h, D-BTX exhibited maximum signal intensity with minimal dispersion, indicative of controlled diffusion at the injection site.
Conclusion
This PEGylated dendrimer-Botox nanoconjugate provides a stable, muscle-targeting, and imageable platform, which surmounts some of the main drawbacks in current clinical applications.
Zitieren
APA
Ajdary, N., Davoudi, M., Mehrizi, T. Z., Ardestani, M. S., Marnani, H. N., Shahmabadi, H. E., & Ajdary, N. (2026). Development and Characterization of Colloidally Stable Dendrimer–Botox Conjugates for Targeted Muscle Delivery and Radiolabeled Imaging. Pharmaceutical Sciences, 32(2), 201-218. https://doi.org/10.34172/ps.026.42832
Vancouver
Ajdary N, Davoudi M, Mehrizi TZ, Ardestani MS, Marnani HN, Shahmabadi HE, et al. Development and Characterization of Colloidally Stable Dendrimer–Botox Conjugates for Targeted Muscle Delivery and Radiolabeled Imaging. Pharmaceutical Sciences. 2026;32(2):201-218. doi:10.34172/ps.026.42832
BibTeX
@article{Ajdary2026,
author = {Ajdary, Nazanin and Davoudi, Maryam and Mehrizi, Tahereh Zadeh and Ardestani, Mehdi Shafiee and Marnani, Hasti Nequi and Shahmabadi, Hasan Ebrahimi and Ajdary, Niloofar},
title = {Development and Characterization of Colloidally Stable Dendrimer–Botox Conjugates for Targeted Muscle Delivery and Radiolabeled Imaging},
journal = {Pharmaceutical Sciences},
year = {2026},
volume = {32},
number = {2},
pages = {201--218},
doi = {10.34172/ps.026.42832}
}
EUVIMED